See more : Wereldhave N.V. (WHA.AS) Income Statement Analysis – Financial Results
Complete financial analysis of Precigen, Inc. (PGEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Precigen, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- ePlay Digital Inc. (EPYFF) Income Statement Analysis – Financial Results
- Altamin Limited (AZI.AX) Income Statement Analysis – Financial Results
- Shanghai Yanhua Smartech Group Co., Ltd. (002178.SZ) Income Statement Analysis – Financial Results
- Singulus Technologies AG (SGTSY) Income Statement Analysis – Financial Results
- Daxin Materials Corporation (5234.TW) Income Statement Analysis – Financial Results
Precigen, Inc. (PGEN)
About Precigen, Inc.
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.23M | 26.91M | 103.87M | 103.18M | 90.72M | 160.57M | 230.98M | 190.93M | 173.61M | 71.93M | 23.76M | 13.93M | 8.01M |
| Cost of Revenue | 6.12M | 6.34M | 58.39M | 55.51M | 61.40M | 63.29M | 62.79M | 61.64M | 63.93M | 19.26M | 48.17M | 64.03M | 0.00 |
| Gross Profit | 106.00K | 20.57M | 45.49M | 47.67M | 29.32M | 97.29M | 168.19M | 129.29M | 109.68M | 52.67M | -24.41M | -50.11M | 8.01M |
| Gross Profit Ratio | 1.70% | 76.44% | 43.79% | 46.20% | 32.32% | 60.59% | 72.82% | 67.72% | 63.18% | 73.22% | -102.71% | -359.85% | 100.00% |
| Research & Development | 48.61M | 47.17M | 50.14M | 41.64M | 101.88M | 404.59M | 143.21M | 112.14M | 147.48M | 58.98M | 48.17M | 64.19M | 70.23M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 137.81M | 146.10M | 142.32M | 109.06M | 63.65M | 33.62M | 24.90M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 40.42M | 48.01M | 74.12M | 91.70M | 100.84M | 137.81M | 146.10M | 142.32M | 109.06M | 63.65M | 33.62M | 24.90M | 18.30M |
| Other Expenses | 0.00 | 1.54M | -330.00K | -165.00K | 3.45M | 630.00K | 1.01M | 1.70M | 1.31M | -168.00K | -162.00K | -101.00K | -1.00K |
| Operating Expenses | 84.18M | 95.18M | 124.26M | 133.35M | 202.72M | 542.39M | 289.31M | 254.45M | 256.54M | 122.63M | 81.78M | 89.08M | 90.44M |
| Cost & Expenses | 95.15M | 101.52M | 182.65M | 188.86M | 264.12M | 605.68M | 352.10M | 316.09M | 320.47M | 141.89M | 81.78M | 89.08M | 90.44M |
| Interest Income | 3.24M | 133.00K | 1.62M | 2.45M | 3.87M | 19.08M | 19.49M | 10.19M | 1.88M | 806.00K | 166.00K | 5.00K | 0.00 |
| Interest Expense | 468.00K | 6.77M | 18.89M | 18.40M | 17.67M | 8.53M | 611.00K | 861.00K | 1.24M | 666.00K | 141.00K | 57.00K | 183.00K |
| Depreciation & Amortization | 6.67M | 7.19M | 8.14M | 15.04M | 16.14M | 24.11M | 31.15M | 24.57M | 17.74M | 10.42M | 7.21M | 7.98M | 4.34M |
| EBITDA | -89.23M | -66.00M | -84.07M | -70.41M | -137.46M | -349.06M | -97.94M | -168.72M | -67.99M | -74.64M | -33.56M | -73.83M | -80.76M |
| EBITDA Ratio | -1,433.35% | -267.84% | -74.60% | -81.93% | -185.73% | -272.15% | -49.75% | -70.39% | -87.91% | -103.69% | -247.44% | -485.08% | -974.54% |
| Operating Income | -88.92M | -74.61M | -78.78M | -85.68M | -173.40M | -505.61M | -137.89M | -125.17M | -146.86M | -69.96M | -58.02M | -75.16M | -82.43M |
| Operating Income Ratio | -1,428.48% | -277.25% | -75.84% | -83.04% | -191.14% | -314.88% | -59.70% | -65.56% | -84.60% | -97.26% | -244.20% | -539.73% | -1,028.67% |
| Total Other Income/Expenses | -7.44M | -5.36M | -19.56M | -18.35M | -35.29M | -26.25M | 17.80M | -68.99M | 59.89M | -15.76M | 17.12M | -6.72M | -2.85M |
| Income Before Tax | -96.36M | -79.97M | -96.93M | -103.86M | -208.69M | -536.23M | -129.70M | -194.15M | -86.98M | -85.72M | -40.91M | -81.87M | -85.28M |
| Income Before Tax Ratio | -1,547.98% | -297.17% | -93.31% | -100.66% | -230.03% | -333.95% | -56.15% | -101.69% | -50.10% | -119.17% | -172.17% | -587.96% | -1,064.27% |
| Income Tax Expense | -458.00K | -189.00K | -160.00K | -82.00K | -930.00K | -21.53M | -2.88M | -3.88M | 1.02M | -103.00K | -9.76M | -318.00K | 182.00K |
| Net Income | -95.90M | -79.78M | -96.77M | -103.77M | -207.76M | -509.34M | -117.02M | -186.61M | -84.49M | -81.82M | -38.98M | -81.87M | -85.28M |
| Net Income Ratio | -1,540.63% | -296.47% | -93.16% | -100.58% | -229.00% | -317.20% | -50.66% | -97.74% | -48.67% | -113.75% | -164.06% | -587.96% | -1,064.27% |
| EPS | -0.39 | -0.40 | -0.49 | -0.62 | -1.35 | -3.93 | -0.98 | -1.58 | -0.76 | -0.83 | -0.95 | -14.80 | -15.05 |
| EPS Diluted | -0.39 | -0.40 | -0.49 | -0.62 | -1.35 | -3.93 | -0.98 | -1.58 | -0.76 | -0.83 | -0.95 | -14.80 | -15.05 |
| Weighted Avg Shares Out | 244.54M | 200.36M | 197.76M | 167.07M | 154.14M | 129.52M | 120.00M | 117.98M | 111.07M | 99.17M | 40.95M | 5.53M | 5.66M |
| Weighted Avg Shares Out (Dil) | 244.54M | 200.36M | 197.76M | 167.07M | 154.14M | 129.52M | 120.00M | 117.98M | 111.07M | 99.17M | 40.95M | 5.53M | 5.66M |
Precigen to Participate in the 2022 Wells Fargo Healthcare Conference
Circling Back On Precigen
Precigen Completes Sale of Non-Healthcare Subsidiary Trans Ova Genetics
Precigen, Inc. (PGEN) CEO Helen Sabzevari on Q2 2022 Results - Earnings Call Transcript
Precigen, Inc. (PGEN) Reports Q2 Loss, Lags Revenue Estimates
Precigen Reports Second Quarter and First Half 2022 Financial Results
Analysts Estimate Precigen, Inc. (PGEN) to Report a Decline in Earnings: What to Look Out for
Precigen, Inc. (PGEN) Upgraded to Buy: Here's What You Should Know
This Analyst Believes Precigen's Non-Healthcare Divesture Removes Financial Overhang
Why Precigen Shares Are Gaining Today
Source: https://incomestatements.info
Category: Stock Reports